Baeten D, et al. - Authors evaluated the effectiveness and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS). The study's primary endpoint was not met by the treatment with risankizumab and compared with placebo in patients with active AS this treatment did not demonstrate any evidence of clinically meaningful improvements, thereby, suggesting a probability of IL-23 not being a relevant driver of disease pathogenesis and symptoms in AS.